Foods,
Journal Year:
2023,
Volume and Issue:
12(10), P. 1985 - 1985
Published: May 13, 2023
Sea
buckthorn
(Hippophae
rhamnoides
L.
or
Elaeagnus
L.)
is
a
plant
that
has
long
been
used
as
Chinese
herbal
medicine.
This
species
known
to
contain
numerous
bioactive
components,
including
polyphenols,
fatty
acids,
vitamins,
and
phytosterols,
which
may
be
responsible
for
its
medicinal
value.
In
experiments
both
in
vitro
vivo
(ranging
from
cell
lines
animal
models
human
patients),
sea
shown
positive
effects
on
symptoms
of
metabolic
syndrome;
evidence
suggests
treatment
can
decrease
blood
lipid
content,
pressure,
sugar
levels,
regulate
key
metabolites.
article
reviews
the
main
compounds
present
discusses
their
efficacy
treating
syndrome.
Specifically,
we
highlight
isolated
distinct
tissues;
abdominal
obesity,
hypertension,
hyperglycemia,
dyslipidemia;
potential
mechanisms
action
clinical
applications.
review
provides
insight
into
benefits
buckthorn,
promoting
future
research
this
expansion
buckthorn-based
therapies
Pharmacological Reviews,
Journal Year:
2019,
Volume and Issue:
71(4), P. 596 - 670
Published: Sept. 25, 2019
Foam
cell
formation
and
further
accumulation
in
the
subendothelial
space
of
vascular
wall
is
a
hallmark
atherosclerotic
lesions.
Targeting
foam
lesions
can
be
promising
approach
to
treat
prevent
atherosclerosis.
The
cells
determined
by
balanced
effects
three
major
interrelated
biologic
processes,
including
lipid
uptake,
cholesterol
esterification,
efflux.
Natural
products
are
source
for
new
lead
structures.
Multiple
natural
pharmaceutical
agents
inhibit
thus
exhibit
antiatherosclerotic
capacity
suppressing
and/or
promoting
ester
hydrolysis
This
review
summarizes
recent
findings
on
these
processes
with
demonstrated
potential
target
such
processes.
Discussed
also
future
directions
studying
mechanisms
development
cell-targeted
therapeutic
strategies.
Toxins,
Journal Year:
2020,
Volume and Issue:
12(11), P. 713 - 713
Published: Nov. 12, 2020
Berberine
is
a
plant
metabolite
belonging
to
the
group
of
isoquinoline
alkaloids
with
strong
biological
and
pharmacological
activity.
Currently,
berberine
receiving
considerable
interest
due
its
anticancer
activity
based
on
many
biochemical
pathways,
especially
proapoptotic
anti-inflammatory
Therefore,
growing
number
papers
demands
summarizing
knowledge
research
trends.
The
efficacy
in
breast
colon
cancers
seems
be
most
promising
aspect.
Many
focus
novel
therapeutic
strategies
new
formulations
or
search
for
active
derivatives.
very
important
as
regards
sensitization
support
therapy
combination
well-known
but
some
cases
inefficient
therapeutics.
compound
being
assessed
clinical
trials
one
intensively
examined
natural
agents.
Biomedicine & Pharmacotherapy,
Journal Year:
2020,
Volume and Issue:
133, P. 110984 - 110984
Published: Nov. 10, 2020
The
increased
incidence
of
metabolic
diseases
(e.g.,
diabetes
and
obesity)
has
seriously
affected
human
health
life
safety
worldwide.
It
is
great
significance
to
find
effective
drugs
from
natural
compounds
treat
diseases.
Berberine
(BBR),
an
important
quaternary
benzylisoquinoline
alkaloid,
exists
in
many
traditional
medicinal
plants.
In
recent
years,
BBR
received
widespread
attention
due
its
good
potential
the
treatment
order
promote
basic
research
clinical
application
BBR,
this
review
provides
a
timely
comprehensive
summary
pharmacological
advances
five
diseases,
including
type
2
mellitus,
obesity,
non-alcoholic
fatty
liver
disease,
hyperlipidemia,
gout.
Both
animal
studies
have
proved
that
therapeutic
effects
on
these
are
based
regulating
various
aspects
pathophysiological
procedures.
For
example,
it
can
insulin
secretion,
improve
resistance,
inhibit
lipogenesis,
alleviate
adipose
tissue
fibrosis,
reduce
hepatic
steatosis,
gut
microbiota
disorders.
Collectively,
may
be
promising
drug
candidate
for
More
studies,
especially
trials,
needed
further
confirm
molecular
mechanisms
targets.
addition,
large-scale,
long-term
multi-center
trials
necessary
evaluate
efficacy
Acta Pharmaceutica Sinica B,
Journal Year:
2020,
Volume and Issue:
10(12), P. 2299 - 2312
Published: June 30, 2020
Programmed
cell
death-1
(PD-1)/programmed
death
ligand-1
(PD-L1)
blocking
therapy
has
become
a
major
pillar
of
cancer
immunotherapy.
Compared
with
antibodies
targeting,
small-molecule
checkpoint
inhibitors
which
have
favorable
pharmacokinetics
are
urgently
needed.
Here
we
identified
berberine
(BBR),
proven
anti-inflammation
drug,
as
negative
regulator
PD-L1
from
set
traditional
Chinese
medicine
(TCM)
chemical
monomers.
BBR
enhanced
the
sensitivity
tumour
cells
to
co-cultured
T-cells
by
decreasing
level
in
cells.
In
addition,
exerted
its
antitumor
effect
Lewis
tumor
xenograft
mice
through
enhancing
tumor-infiltrating
T-cell
immunity
and
attenuating
activation
immunosuppressive
myeloid-derived
suppressor
(MDSCs)
regulatory
(Tregs).
triggered
degradation
ubiquitin
(Ub)/proteasome-dependent
pathway.
Remarkably,
selectively
bound
glutamic
acid
76
constitutive
photomorphogenic-9
signalosome
5
(CSN5)
inhibited
PD-1/PD-L1
axis
deubiquitination
activity,
resulting
ubiquitination
PD-L1.
Our
data
reveals
previously
unrecognized
mechanism
BBR,
suggesting
is
immune
inhibitor
for
treatment.
npj Biofilms and Microbiomes,
Journal Year:
2021,
Volume and Issue:
7(1)
Published: April 16, 2021
Abstract
Trimethylamine-
N
-oxide
(TMAO),
a
derivative
from
the
gut
microbiota
metabolite
trimethylamine
(TMA),
has
been
identified
to
be
an
independent
risk
factor
for
promoting
atherosclerosis.
Evidences
suggest
that
berberine
(BBR)
could
used
treat
obesity,
diabetes
and
atherosclerosis,
however,
its
mechanism
is
not
clear
mainly
because
of
poor
oral
bioavailability.
Here,
we
show
BBR
attenuated
TMA/TMAO
production
in
C57BL/6J
ApoE
KO
mice
fed
with
choline-supplemented
chow
diet,
mitigated
atherosclerotic
lesion
areas
mice.
Inhibition
by
BBR-modulated
was
proved
single-dose
administration
d9-choline
vivo.
Metagenomic
analysis
cecal
contents
demonstrated
altered
composition,
microbiome
functionality,
cutC
/
cntA
gene
abundance.
Furthermore,
shown
inhibit
choline-to-TMA
conversion
TMA-producing
bacteria
vitro
microbial
consortium
fecal
samples
choline-fed
human
volunteers,
result
confirmed
transplantation
These
results
offer
new
insights
into
mechanisms
responsible
anti-atherosclerosis
effects
BBR,
which
inhibits
commensal
TMA
via
remodeling.
Signal Transduction and Targeted Therapy,
Journal Year:
2024,
Volume and Issue:
9(1)
Published: March 1, 2024
Abstract
Peroxisome
proliferator-activated
receptor
gamma
coactivator-1
(PGC-1)
family
(PGC-1s),
consisting
of
three
members
encompassing
PGC-1α,
PGC-1β,
and
PGC-1-related
coactivator
(PRC),
was
discovered
more
than
a
quarter-century
ago.
PGC-1s
are
essential
coordinators
many
vital
cellular
events,
including
mitochondrial
functions,
oxidative
stress,
endoplasmic
reticulum
homeostasis,
inflammation.
Accumulating
evidence
has
shown
that
implicated
in
diseases,
such
as
cancers,
cardiac
diseases
cardiovascular
neurological
disorders,
kidney
motor
system
metabolic
disorders.
Examining
the
upstream
modulators
co-activated
partners
identifying
critical
biological
events
modulated
by
downstream
effectors
contribute
to
presentation
elaborate
network
PGC-1s.
Furthermore,
discussing
correlation
between
well
summarizing
therapy
targeting
helps
make
individualized
precise
intervention
methods.
In
this
review,
we
summarize
basic
knowledge
regarding
molecular
regulatory
network,
discuss
physio-pathological
roles
human
review
application
PGC-1s,
diagnostic
prognostic
value
several
therapies
pre-clinical
studies,
suggest
directions
for
future
investigations.
This
presents
immense
potential
treatment
hopefully
facilitates
promotion
new
therapeutic
targets.
